De Novo JAK2 V617 F Positive AML: The Picture is Getting Clearer

被引：0
作者：
Ghosh, Kanjaksha [1 ]
Ghosh, Kinjalka [2 ]
机构：
[1] Surat Raktadan Kendra & Res Ctr, Haematol & Transfus Med, Surat, India
[2] Tata Canc Ctr, Clin Biochem, Ernest Borges Rd, Mumbai, Maharashtra, India
来源：
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION | 2019年 / 35卷 / 02期
关键词：
ACUTE MYELOID-LEUKEMIA;
D O I：
10.1007/s12288-018-1041-y
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：360 / 361
页数：2
相关论文
共 50 条
  • [31] IgG-lymphoplasmacytic lymphoma following polycythemia vera: JAK2 V617F and MYD88 L265P mutations separated in the same house
    Luisa Anelli
    Antonella Zagaria
    Angela Minervini
    Paola Casieri
    Nicoletta Coccaro
    Giuseppina Tota
    Crescenzio Francesco Minervini
    Claudia Brunetti
    Luciana Impera
    Alessandra Ricco
    Angelo Cellamare
    Giorgina Specchia
    Francesco Albano
    Annals of Hematology, 2014, 93 : 1605 - 1607
  • [32] A patient with a 20-year lag phase between JAK2-V617F+myeloproliferation and NPM1-mutated AML arguing against a common origin of disease
    Roug, Anne Stidsholt
    Nyvold, Charlotte Guldborg
    Juhl-Christensen, Caroline
    Christensen, Mariann
    Schnittger, Susanne
    Hokland, Peter
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2011, 87 (05) : 461 - 463
  • [33] SOCS-mediated downregulation of mutant Jak2 ( V617F, T875N and K539L) counteracts cytokine-independent signaling
    Haan, S.
    Wueller, S.
    Kaczor, J.
    Rolvering, C.
    Noecker, T.
    Behrmann, I.
    Haan, C.
    ONCOGENE, 2009, 28 (34) : 3069 - 3080
  • [34] After 10 years of JAK2V617F: Disease biology and current management strategies in polycythaemia vera
    Grinfeld, Jacob
    Godfrey, Anna L.
    BLOOD REVIEWS, 2017, 31 (03) : 101 - 118
  • [35] Erythroid lineage-restricted expression of Jak2V617F is sufficient to induce a myeloproliferative disease in mice
    Akada, Hajime
    Akada, Saeko
    Hutchison, Robert E.
    Mohi, Golam
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (09): : 1389 - 1393
  • [36] Relevance of JAK2V617F positivity to hematological diseases - survey of samples from a clinical genetics laboratory
    Wanming Zhao
    Rufei Gao
    Jiyun Lee
    Shu Xing
    Wanting T Ho
    Xueqi Fu
    Shibo Li
    Zhizhuang J Zhao
    Journal of Hematology & Oncology, 4
  • [37] Locked nucleic acid probes for enhanced detection of FLT3 D835/I836, JAK2 V617F and NPM1 mutations
    Warshawsky, Ilka
    Mularo, Frank
    JOURNAL OF CLINICAL PATHOLOGY, 2011, 64 (10) : 905 - 910
  • [38] Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms
    Prestipino, Alessandro
    Emhardt, Alica J.
    Aumann, Konrad
    O'Sullivan, David
    Gorantla, Sivahari P.
    Duquesne, Sandra
    Melchinger, Wolfgang
    Braun, Lukas
    Vuckovic, Slavica
    Boerries, Melanie
    Busch, Hauke
    Halbach, Sebastian
    Pennisi, Sandra
    Poggio, Teresa
    Apostolova, Petya
    Veratti, Pia
    Hettich, Michael
    Niedermann, Gabriele
    Bartholomae, Mark
    Shoumariyeh, Khalid
    Jutzi, Jonas S.
    Wehrle, Julius
    Dierks, Christine
    Becker, Heiko
    Schmitt-Graeff, Annette
    Follo, Marie
    Pfeifer, Dietmar
    Rohr, Jan
    Fuchs, Sebastian
    Ehl, Stephan
    Hartl, Frederike A.
    Minguet, Susana
    Miething, Cornelius
    Heidel, Florian H.
    Kroeger, Nicolaus
    Triviai, Ioanna
    Brummer, Tilman
    Finke, Jurgen
    Illert, Anna L.
    Ruggiero, Eliana
    Bonini, Chiara
    Duyster, Justus
    Pahl, Heike L.
    Lane, Steven W.
    Hill, Geoffrey R.
    Blazar, Bruce R.
    von Bubnoff, Nikolas
    Pearce, Erika L.
    Zeiser, Robert
    SCIENCE TRANSLATIONAL MEDICINE, 2018, 10 (429)
  • [39] Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms
    Chen, Edwin
    Schneider, Rebekka K.
    Breyfogle, Lawrence J.
    Rosen, Emily A.
    Poveromo, Luke
    Elf, Shannon
    Ko, Amy
    Brumme, Kristina
    Levine, Ross
    Ebert, Benjamin L.
    Mullally, Ann
    BLOOD, 2015, 125 (02) : 327 - 335
  • [40] Leukemic transformation driven by an ASXL1 mutation after a JAK2V617F-positive primary myelofibrosis: clonal evolution and hierarchy revealed by next-generation sequencing
    Francisca Ferrer-Marín
    Beatriz Bellosillo
    Luz Martínez-Avilés
    Gloria Soler
    Pablo Carbonell
    Ginés Luengo-Gil
    Eva Caparrós
    José M Torregrosa
    Carlos Besses
    Vicente Vicente
    Journal of Hematology & Oncology, 6
12345